IN 289/2024 outlines the criteria for the optimized analysis procedure, which relies on assessments by Equivalent Foreign Regulatory Authorities (AREE) for the registration and post-registration of medicines, biological products, vaccines, and Active Pharmaceutical Ingredient Dossier (CADIFA).